Document Detail

Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
MedLine Citation:
PMID:  18093878     Owner:  NLM     Status:  MEDLINE    
Lamotrigine (LTG, Lamictal), one of the newer antiepileptic drugs, was admitted to the Dutch market in 1996. It was first used as adjunctive therapy and later as a monotherapy in partial and generalized epilepsy. All patients who started on LTG in 1996 or 1997 in the Epilepsy Centre Kempenhaeghe (n=314) were enrolled in this study and followed for 48 months. The data indicate that the retention rates for LTG after 1, 2, 3, and 4 years are respectively 74.4, 69.3, 63.1, and 55.6%. Patients with normal cognitive function were more likely to continue than patients with mental retardation. The main reason for discontinuing LTG therapy was lack of efficacy (19.1%). Four patients (1.4%) were seizure-free for the total follow-up period of 48 months. The most frequently reported negative side effects were dizziness and headache, both in patients who continued and in those who discontinued therapy. A large percentage of patients also reported positive side effects like "feeling/being more active" and "feeling more clear/more responsive." For the whole patient group, the plasma level of LTG was measured 277 times. Plasma levels of LTG were influenced by the patients' comedications. Plasma levels of LTG in groups taking LTG in monotherapy, LTG plus an inducer, and LTG plus valproate were 8.7, 4.8, and 8.7 mg/L, respectively. The correlation between measured plasma level and dose confirm the manufacturer's dose recommendations. The manufacturer recommends half the dosage of lamotrigine monotherapy when the patient also uses valproate. When the patient uses an inducer, the dosage of LTG must be two times the dose used in monotherapy.
H P R Bootsma; A M Vos; J Hulsman; D Lambrechts; L Leenen; M Majoie; M Savelkoul; A Schellekens; A P Aldenkamp
Related Documents :
2345618 - Prolonged postictal encephalopathy.
18589058 - Status epilepticus in central nervous system infections: an experience from a developin...
9454978 - Neurocysticercosis in children. clinical experience in 122 patients.
8660038 - Benign partial epilepsy in infancy.
2265778 - Rectal mucosal dysplasia in crohn's disease.
6107388 - Cryptorchidism and testicular cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Epilepsy & behavior : E&B     Volume:  12     ISSN:  1525-5050     ISO Abbreviation:  Epilepsy Behav     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-14     Completed Date:  2008-03-18     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  100892858     Medline TA:  Epilepsy Behav     Country:  United States    
Other Details:
Languages:  eng     Pagination:  262-8     Citation Subset:  IM    
Department of Neurology, Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / blood,  therapeutic use*
Child, Preschool
Drug Resistance
Drug Therapy, Combination
Epilepsy / classification,  drug therapy*
Follow-Up Studies
Kaplan-Meier Estimate
Middle Aged
Patient Dropouts / statistics & numerical data
Patient Satisfaction
Seizures / classification,  prevention & control*
Statistics, Nonparametric
Treatment Outcome
Triazines / blood,  therapeutic use*
Reg. No./Substance:
0/Anticonvulsants; 0/Triazines; U3H27498KS/lamotrigine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hybrid particle swarm optimization and tabu search approach for selecting genes for tumor classifica...
Next Document:  Low nanomolar concentration of mercury chloride increases vascular reactivity to phenylephrine and l...